The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease
DOI:
https://doi.org/10.2340/sju.v61.45715Keywords:
Prostate cancer, guideline, recurrence, treatment, metastatic, castration resistantAbstract
Objective: This article presents a summary of the 2025 Swedish prostate cancer guidelines, focusing on recurrence after local treatment, metastatic disease, and castration-resistant prostate cancer.
Results: The 2025 Swedish guidelines introduce several important updates. Prostate specific membrane antigen (PSMA)-PET/CT is recommended only when PSA exceeds 0.2 µg/L, and reporting should follow the defined PSMA-RADS-scale. PSMA-PET/CT is preferred over lymph-node dissection for staging. A strong recommendation is issued for radiotherapy to the primary tumour in all oligometastatic men with a life expectancy > 5 years, whereas metastasis-directed therapy is restricted to clinical trials. Systemic treatment pathways now prioritise androgen receptor pathway inhibitors (ARPI) plus androgen deprivation therapy (ADT), with triple therapy (including docetaxel) used more selectively. Pathway-specific staging algorithms have been revised. The oly (ADP-ribose) polymerase inhibitor (PARPi) section has expanded, with broader genomic-based selection and integration into treatment sequencing. Two new chapters and an appendix address cardiovascular risk assessment before ARPI or chemotherapy. Supportive care is substantially strengthened.
Compared with the EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2025, the Swedish guidelines 2025 applies PSMA-PET/CT more conservatively, restricts PSMA-guided nodal salvage therapy, and issues a more universal recommendation for local radiotherapy in oligometastatic disease. The Swedish guidelines 2025 prioritise ARPI + ADT and limit triple therapy and PARPi combinations due to regulatory and reimbursement constraints. PARPi are largely reserved for BRCA1/2-mutated disease. The Swedish guidelines 2025 provide a more comprehensive framework for rehabilitation and survivorship.
Conclusions: The 2025 Swedish prostate cancer guidelines introduce multiple new recommendations and differ in several aspects from the European guidelines.
Downloads
References
Nationellt vårdprogram prostatacancer 10.0. Regionala Cancercentrum i Samverkan; 025. [Cited date: 30 November 2025] Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/prostatacancer/vardprogram/
Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024.
https://doi.org/10.1016/j.eururo.2024.03.027 DOI: https://doi.org/10.1016/j.eururo.2024.03.027
Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86(2):164–182.
https://doi.org/10.1016/j.eururo.2024.04.010 DOI: https://doi.org/10.1016/j.eururo.2024.04.010
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. 2022;56(4):265–273.
https://doi.org/10.1080/21681805.2022.2094462 DOI: https://doi.org/10.1080/21681805.2022.2094462
Bratt O, Carlsson S, Fransson P, et al. The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. Scand J Urol. 2022;56(4):278–284.
https://doi.org/10.1080/21681805.2022.2093396 DOI: https://doi.org/10.1080/21681805.2022.2093396
Cazzaniga W, Ventimiglia E, Alfano M, et al. Mini review on the use of clinical cancer registers for prostate cancer: the National Prostate Cancer Register (NPCR) of Sweden. Front Med (Lausanne). 2019;6:51.
https://doi.org/10.3389/fmed.2019.00051 DOI: https://doi.org/10.3389/fmed.2019.00051
Nugin H, Folkvaljon Y, Damber JE, et al. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scand J Urol. 2018;52(4):277–284.
https://doi.org/10.1080/21681805.2018.1512650 DOI: https://doi.org/10.1080/21681805.2018.1512650
Taylor JA, 3rd, Koff SG, Dauser DA, et al. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int. 2006;98(3):540–543.
https://doi.org/10.1111/j.1464-410X.2006.06294.x DOI: https://doi.org/10.1111/j.1464-410X.2006.06294.x
Tilki D, Preisser F, Graefen M, et al. External validation of the european association of urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European Cohort. Eur Urol. 2019;75(6):896–900.
https://doi.org/10.1016/j.eururo.2019.03.016 DOI: https://doi.org/10.1016/j.eururo.2019.03.016
Rafiei Alavi N, Rahmani M, Gupta A, et al. PSMA-RADS to improve evaluation and management of prostate cancer. Abdom Radiol (NY). 2025;50(7):3272–3283.
https://doi.org/10.1007/s00261-024-04738-2 DOI: https://doi.org/10.1007/s00261-024-04738-2
Ghadjar P, Hayoz S, Bernhard J, et al. Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09/10 randomized phase 3 trial. Eur Urol. 2021;80(3):306–315. DOI: https://doi.org/10.1200/JCO.2021.39.6_suppl.194
https://doi.org/10.1016/j.eururo.2021.05.033 DOI: https://doi.org/10.1016/j.eururo.2021.05.033
Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–428.
https://doi.org/10.1056/NEJMoa1607529 DOI: https://doi.org/10.1056/NEJMoa1607529
Sargos P, Chabaud S, Latorzeff I, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341–1352.
https://doi.org/10.1016/S1470-2045(20)30454-X DOI: https://doi.org/10.1016/S1470-2045(20)30454-X
Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399(10338):1886–1901.
https://doi.org/10.1016/S0140-6736(21)01790-6 DOI: https://doi.org/10.1016/S0140-6736(21)01790-6
Ost P, Siva S, Brabrand S, et al. Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol. 2025;26(6):695–706. DOI: https://doi.org/10.1016/S1470-2045(25)00197-4
Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453–1465.
https://doi.org/10.1056/NEJMoa2303974 DOI: https://doi.org/10.1056/NEJMoa2303974
Shore ND, Luz MA, De Giorgi U, et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2026 Feb 5;394(6):563–575.
https://doi.org/10.1056/NEJMoa2510310 DOI: https://doi.org/10.1056/NEJMoa2510310
Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171(3):1141–1147.
https://doi.org/10.1097/01.ju.0000113794.34810.d0 DOI: https://doi.org/10.1097/01.ju.0000113794.34810.d0
Valle LF, Lehrer EJ, Markovic D, et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol. 2021;80(3):280–292. DOI: https://doi.org/10.1016/j.eururo.2020.11.010
Urabe F, Kimura S, Tashiro K, et al. Prognostic value of PSA bounce in prostate cancer following definitive radiation therapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021;24(4):976–985.
https://doi.org/10.1038/s41391-021-00372-x DOI: https://doi.org/10.1038/s41391-021-00372-x
Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline Part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024;211(4):509–517.
https://doi.org/10.1097/JU.0000000000003892 DOI: https://doi.org/10.1097/JU.0000000000003892
Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005;23(4):826–831. DOI: https://doi.org/10.1200/JCO.2005.02.111
Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–166.
https://doi.org/10.1016/j.radonc.2020.04.003 DOI: https://doi.org/10.1016/j.radonc.2020.04.003
Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–2366. DOI: https://doi.org/10.1016/S0140-6736(18)32486-3
Parker CC, James ND, Brawley CD, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial. PLoS Med. 2022;19(6):e1003998.
Bossi A, Foulon S, Maldonado X, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2024;404(10467):2065–2076. DOI: https://doi.org/10.1016/S0140-6736(24)01865-8
Burdett S, Boeve LM, Ingleby FC, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol. 2019;76(1):115–124.
https://doi.org/10.1016/j.eururo.2019.02.003 DOI: https://doi.org/10.1016/j.eururo.2019.02.003
Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol. 2023;24(5):443–456. DOI: https://doi.org/10.1016/S1470-2045(23)00148-1
Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294–2303.
https://doi.org/10.1200/JCO.20.03488 DOI: https://doi.org/10.1200/JCO.20.03488
Sweeney CJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(4):323–334. DOI: https://doi.org/10.1016/S1470-2045(23)00063-3
Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study f androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–2986. DOI: https://doi.org/10.1200/JCO.19.00799
Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–2196.
https://doi.org/10.1056/NEJMoa2004325 DOI: https://doi.org/10.1056/NEJMoa2004325
Murthy V, Maitre P, Kannan S, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39(11):1234–1242. DOI: https://doi.org/10.1200/JCO.20.03282
Graefen M, Falkenbach F, Maurer T, et al. Best systemic therapy with or without radical prostatectomy in the management of men with oligometastatic prostate cancer: the RAMPP randomised controlled trial. Eur Urol. 2025 Oct 3:S0302-2838(25)04687-1.
https://doi.org/10.1016/j.eururo.2025.09.4144 DOI: https://doi.org/10.1016/j.eururo.2025.09.4144
Odat RM, Jain H, Jain J, et al. Risk of cardiovascular disease following degarelix versus gonadotropin-releasing hormone agonists in patients with prostate cancer: a systematic review and meta-analysis. Urol Oncol. 2025;43(6):359–369. DOI: https://doi.org/10.1016/j.urolonc.2024.12.277
Yan M, Moideen N, Bratti VF, et al. Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence. Br J Radiol. 2020;93(1116):20200496.
https://doi.org/10.1259/bjr.20200496 DOI: https://doi.org/10.1259/bjr.20200496
Fizazi K, Azad AA, Matsubara N, et al. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet. 2025;406(10502):461–474. DOI: https://doi.org/10.1016/S0140-6736(25)00683-X
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746. DOI: https://doi.org/10.1056/NEJMoa1503747
Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399(10336):1695–1707.
https://doi.org/10.1016/S0140-6736(22)00367-1 DOI: https://doi.org/10.1016/S0140-6736(22)00367-1
Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132–1142. DOI: https://doi.org/10.1056/NEJMoa2119115
Alverbratt C, Vikman H, Hjalm Eriksson M, et al. Time difference in retrieving clinical information in Patient-overview Prostate Cancer compared to electronic health records. Scand J Urol. 2022;56(2):95–101.
https://doi.org/10.1080/21681805.2021.2014561 DOI: https://doi.org/10.1080/21681805.2021.2014561
Saad F, Clarke NW, Oya M, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(10):1094–1108. DOI: https://doi.org/10.1016/S1470-2045(23)00382-0
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–1103.
https://doi.org/10.1056/NEJMoa2107322 DOI: https://doi.org/10.1056/NEJMoa2107322
Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719–732. DOI: https://doi.org/10.1056/NEJMoa2214676
Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345–2357.
https://doi.org/10.1056/NEJMoa2022485 DOI: https://doi.org/10.1056/NEJMoa2022485
Chen R, Yang D, Tian M, et al. The prognostic role of Geriatric 8 in patients with cancer: a meta-analysis and systematic review. Oncologist. 2025;30(6):oyaf118.
https://doi.org/10.1093/oncolo/oyaf118 DOI: https://doi.org/10.1093/oncolo/oyaf118
Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–4361.
https://doi.org/10.1093/eurheartj/ehac244 DOI: https://doi.org/10.1093/eurheartj/ehac244
Ostergren PB, Kistorp C, Bennedbaek FN, et al. The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. Nature reviews Urology. 2016;13(6):353–364.
https://doi.org/10.1038/nrurol.2016.67 DOI: https://doi.org/10.1038/nrurol.2016.67
Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32(4):335–346.
https://doi.org/10.1200/JCO.2013.49.5523 DOI: https://doi.org/10.1200/JCO.2013.49.5523
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Johan Stranne, Elin Axen, Ola Bratt, Stefan Carlsson, Jon Kindblom, Kimia Kohestani, Anna Kristiansen, Ingela Franck Lissbrant, Gabriel Moise, Elinor Nemlander, David Robinsson, Christian Torbrand, Elin Trägårdh, Jonas Wallström, Camilla Wennerberg, Camilla Thellenberg Karlsson
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
